Savara INC

Savara Inc. announced the approval of significant amendments to its Certificate of Incorporation and 2024 Omnibus Incentive Plan, alongside executive transitions, during its annual stockholder meeting.

Savara Inc. has entered into a new lease agreement for approximately 10,795 square feet of office space in Yardley, PA, to serve as its new headquarters, commencing July 1, 2026.

Savara Inc. amended its loan agreement with Hercules Capital, Inc., restructuring access to $75 million in additional term loans contingent on FDA approval of MOLBREEVI and extending financial covenant compliance dates.

Savara Inc. updated its corporate presentation, detailing positive Phase 3 results for MOLBREEVI in autoimmune PAP and outlining its commercialization strategy.

Savara Inc. announced the pricing of a $130.0 million public offering of common stock and pre-funded warrants to fund clinical development and commercialization activities.

Savara Inc. announced a $75 million non-dilutive royalty funding agreement with RTW Investments, LP to support the potential U.S. launch of its investigational drug MOLBREEVI for autoimmune PAP, contingent on FDA approval.

Savara Inc. reported a wider net loss in Q1 2026 due to increased R&D and G&A expenses, alongside an FDA review extension for MOLBREEVI.

Savara Inc. reported increased net losses for Q3 and the nine months ended September 30, 2025, while securing significant post-period funding and planning to resubmit its MOLBREEVI BLA in December 2025 following an FDA Refusal to File.

Savara Inc. reported increased net losses and R&D expenses in Q2 2025, following an FDA Refusal to File letter for its lead drug candidate, MOLBREEVI, with resubmission planned for December 2025.

Savara Inc. finalizes its BLA submission to the FDA for molgramostim and secures a $200 million debt facility with Hercules Capital, while reporting a net loss for Q1 2025.

Savara Inc. saw a significant increase in research and development expenses in the third quarter of 2024, while also progressing towards a Biological License Application submission for its lead drug candidate.

Savara Inc., a clinical-stage biopharmaceutical company, announced its financial results for the second quarter of 2024, highlighting increased research and development spending and a recent $100 million capital raise.

Savara Inc. announced its Biologics License Application for MOLBREEVI in autoimmune PAP was formally filed by the FDA and granted Priority Review in February 2026, following a resubmission in December 2025 after an initial Refusal to File letter.

Savara Inc. files an amendment to its annual report on Form 10-K to include its Insider Trading and Disclosure Policy, which was inadvertently omitted from the original filing.

Savara Inc. finalizes its biologics license application to the FDA for molgramostim and secures a $200 million debt facility to advance its rare respiratory disease program.

Savara Inc.'s 10-K filing highlights the company's focus on its sole product candidate, molgramostim, for treating autoimmune pulmonary alveolar proteinosis (aPAP), while also detailing its financial position and risks.

Robert Matthew Lutz, Chief Fin. & Operating Officer of Savara Inc, reported multiple transactions in common stock on July 15, 2026.

Savara Inc.'s Chief Financial Officer, David L. Lowrance, exercised multiple stock options and subsequently disposed of shares for tax planning purposes on March 18, 2026.

Savara Inc. Director David A. Ramsay sold 20,000 shares of common stock at a weighted average price of $6.061 to cover tax obligations from restricted stock unit vesting.

Savara Inc.'s Chief Financial Officer, David L. Lowrance, reported planned dispositions of 94,960 common shares through tax-related withholding and a bona fide gift.

Savara Inc. CEO Matthew Pauls reported the disposition of common stock, including shares withheld for tax obligations and a gift to a trust.

Savara Inc.'s Chief Operating Officer, Robert Matthew Lutz, disposed of 67,760 shares of common stock to cover tax liabilities related to restricted stock unit vesting.

Savara Inc. seeks stockholder approval for a share authorization increase and amendments to its 2024 Omnibus Incentive Plan ahead of potential commercialization.

Savara Inc. announces its 2025 Annual Meeting of Stockholders to be held on June 5, 2025, with proposals including the election of directors, ratification of the accounting firm, and executive compensation.

Savara Inc. will hold its 2025 Annual Meeting of Stockholders virtually on June 5, 2025, to vote on director elections, auditor ratification, executive compensation, and other matters.

Savara Inc. will hold its annual stockholder meeting on June 6, 2024, to vote on key proposals including the election of directors, approval of the 2024 Omnibus Incentive Plan, and ratification of the appointment of RSM US LLP as the independent auditor.

Savara Inc. is set to hold its 2024 Annual Meeting of Stockholders on June 6, 2024, featuring proposals including director elections, incentive plan approval, officer exculpation amendment, accounting firm ratification, and executive compensation advisory vote.

New Enterprise Associates and its affiliates reported a decrease in their beneficial ownership of Savara Inc. common stock to 12.0% due to an increase in the number of outstanding shares.

Bain Capital Life Sciences and its affiliates have filed an Amendment No. 4 to their Schedule 13D, reaffirming their collective beneficial ownership of 9.99% of Savara Inc.'s common stock, totaling 17,600,621 shares, constrained by a beneficial ownership blocker on pre-funded warrants.

Frazier Life Sciences entities and individuals have filed an amended Schedule 13G, detailing their beneficial ownership in Savara Inc. common stock.

Nantahala Capital Management, LLC and its managing members reported a 3.61% beneficial ownership stake in Savara Inc. common stock as of December 31, 2025.

Farallon Capital Management updates its Schedule 13G filing for Savara Inc., detailing changes in beneficial ownership and internal management personnel.

BlackRock, Inc. has reported a 5.4% beneficial ownership stake in Savara Inc.'s common stock as of December 31, 2025.

A group of Venrock entities and individuals has reported a 7.3% beneficial ownership stake in Savara Inc. as of September 30, 2025.

Nantahala Capital Management, along with Wilmot B. Harkey and Daniel Mack, reported beneficial ownership of 5.08% of Savara Inc.'s common stock as of September 30, 2025.